RKTO stock forecast, quote, news & analysis
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems... Show more
Why Rocket One (RKTO) Stock Is Down -35% in the Last 30 Days
Key Takeaways
- Rocket One (RKTO) shares fell roughly 35% over the trailing 30-day period, sliding from $0.71 to $0.4622.
- The decline extends a broader pullback, with the stock down about 44% from early August.
- The drop occurred despite a string of corporate announcements, underscoring the stock's speculative, high-volatility profile.
- Rocket One is an early-stage company repositioning from legacy biotech into space, defense, and AI semiconductor infrastructure.
- A positive HT-001 interim efficacy readout led the company to end its Phase 2a trial early and plan for a Phase 3 program.
- For deeper analysis, explore Rocket One's Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies are positioning in this stock by visiting Trending AI Robots.
Rocket One (RKTO) Company Overview and Market Position
Rocket One Inc. is a Hoboken, New Jersey-based technology company that was formerly known as Hoth Therapeutics. In May 2026, the company completed a strategic repositioning, adopted the Rocket One name, and began trading on the Nasdaq Capital Market under the RKTO ticker, reflecting a pivot toward the orbital economy.
The company operates across two segments: biopharmaceutical and AI semiconductor infrastructure. Its technology ambitions center on licensed spintronic and nanomagnetic computing for AI acceleration and radiation-tolerant, ultra-low-power computing for space and defense applications. The portfolio also includes Swarm Stage AI, a drone-swarm threat-emulation and counter-UAS training platform, and Tracer Drone Technologies, which provides end-to-end drone hardware, software, and training solutions. The legacy biotech pipeline includes HT-001, an investigational topical formulation being studied for skin toxicities tied to EGFR-inhibitor cancer therapies.
Investors follow RKTO because it sits at the intersection of several high-growth themes, including AI hardware, space computing, and defense technology, while still carrying the characteristics of a low-priced, early-stage micro-cap.
Rocket One (RKTO) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, RKTO fell from a closing price of $0.71 to $0.4622, a decline of approximately 34.9%. The move was not a straight line: shares edged lower through early and mid-October, staged a brief rebound around the third week of the month, and then resumed their decline into early November.
The weakness is part of a longer slide. Three months earlier, shares closed near $0.8195, meaning the stock has lost roughly 43.6% over the trailing quarter. The company has also experienced sharp, short-lived rallies during this stretch, including an intraday surge above $0.90 in mid-September, highlighting the outsized volatility that has characterized trading since the rebranding.
What Drove RKTO Stock Price in the Last 30 Days
The past month featured a series of announcements that did not translate into sustained share-price gains. In early October, Rocket One disclosed a patent license agreement with the U.S. Air Force for technology designed to capture and neutralize hostile drones, expanding its counter-UAS portfolio. Later in the month, the company executed a sponsored research agreement with Virginia Commonwealth University to advance SKYMRAM, a skyrmion-based magnetic memory technology with potential applications in next-generation AI chips.
In early November, its biotech subsidiary reported strong interim efficacy results for HT-001, prompting an early conclusion of the Phase 2a trial and plans to pursue a potential Phase 3 program. Despite these developments, the stock continued to trend lower, reflecting several headwinds common to speculative micro-caps: limited commercial revenue, uncertainty around funding and execution, and a shift in sentiment away from the initial post-rebrand enthusiasm. The brief mid-October bounce faded quickly, reinforcing the downward trend.
What Drove RKTO Stock Performance Over the Last Quarter
The quarterly decline reflects the unwinding of a speculative rally that followed the company's transition from a biotech identity to a space and AI-computing story. The rebranding generated a surge of retail interest, but without near-term revenue from its new technology initiatives, that momentum proved difficult to sustain.
Over the three-month period, investors increasingly weighed the company's early-stage, pre-commercial status against the longer timeline required to validate its nanomagnetic chip, spintronic memory, and defense platforms. Broader caution toward small-cap and micro-cap equities also contributed to the pressure. The result has been a steady repricing lower, punctuated by brief spikes that have not held.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. The robots vary widely in strategy, timeframe, and performance metrics, allowing traders to compare approaches that range from short-term signals to longer-horizon models. For investors tracking volatile names like RKTO, these tools provide a data-driven way to monitor shifting momentum and sentiment. Exploring the page can offer a clearer view of how automated systems are currently interpreting market conditions.
RKTO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape RKTO's direction. The first is the HT-001 program, where regulatory feedback from the FDA will determine whether the company can advance into a Phase 3 trial. On the technology side, progress toward the SKYMRAM proof-of-concept milestone and any additional defense or space licensing agreements will be closely watched as validation of the company's pivot.
Investors should also monitor funding and capital-raising activity, given the company's early-stage profile and the potential for shareholder dilution. Broader sentiment toward small-cap equities, along with the pace of commercialization across its drone and semiconductor initiatives, will remain important. As always, these are factors to observe rather than signals of future performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for RKTO turns negative, indicating new downward trend
RKTO saw its Momentum Indicator move below the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In 81 of the 85 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for RKTO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 37 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RKTO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RKTO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where RKTO advanced for three days, in 145 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
RKTO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.217) is normal, around the industry mean (16.360). P/E Ratio (-0.491) is within average values for comparable stocks, (53.310). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.696). Dividend Yield (0.000) settles around the average of (0.434) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (104.492).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. RKTO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RKTO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company to develop therapeutics for patients suffering from eczema
Industry ComputerCommunications